Supernus Pharmaceuticals (SUPN) Earnings Date, Estimates & Call Transcripts $35.43 -0.34 (-0.95%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Supernus Pharmaceuticals Latest Earnings SummaryActual EPS (Nov. 4) $0.69 Beat By $0.25 Consensus EPS (Nov. 4) $0.44 Supernus Pharmaceuticals posted Q3 2024 earnings on November 4, 2024, reporting an EPS of $0.69, which beat the consensus estimate of $0.44 by $0.25. Quarterly revenue rose 14.2% year-over-year to $175.70 million, above the consensus estimate of $157.35 million. With a trailing EPS of $1.07 and a P/E Ratio of 33.11, Supernus Pharmaceuticals' earnings are expected to decrease -40.93% next year, from $2.37 to $1.40 per share. Conference CallConference Call TranscriptSEC 10-Q/10-K FilingPowered by Get Supernus Pharmaceuticals Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Supernus Pharmaceuticals and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataSUPN Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.SUPN Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Supernus Pharmaceuticals Analyst EPS EstimatesCurrent Year EPS Consensus Estimate:$2.37 EPSNext Year EPS Consensus Estimate: $1.40 EPS Supernus Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails11/4/2024Q3 2024$0.44$0.69+$0.25$1.21$157.35M$175.70M8/6/2024Q2 2024$0.39$0.36 -$0.03$0.36$148.83M$168.30M2/27/2024Q4 2023$0.41$0.02 -$0.39$0.02$155.03M$164.30M11/8/2023Q3 2023$0.13-$0.29 -$0.42-$0.29$143.39M$153.88M8/8/2023Q2 2023$0.23-$0.02 -$0.25-$0.02$143.63M$135.56M5/9/2023Q1 2023$0.12$0.29+$0.17$0.29$139.02M$153.80M70%, 80%, 90% Win Rates? Grab Your Free Cheatsheets Today! (Ad)Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets.>> You can grab your FREE, laminated copies right here << 2/28/2023Q4 2022$0.73$0.43 -$0.30$0.43$180.38M$167.33M Supernus Pharmaceuticals Earnings - Frequently Asked Questions When did Supernus Pharmaceuticals announce their last quarterly earnings? Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earning data on Monday, November 4, 2024. Learn more on SUPN's earnings history. What guidance has Supernus Pharmaceuticals issued on next quarter's earnings? Supernus Pharmaceuticals updated its FY 2024 earnings guidance on Monday, November, 4th. The company issued revenue guidance of $630.0 million-$650.0 million, compared to the consensus revenue estimate of $619.5 million. Did Supernus Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, Supernus Pharmaceuticals (NASDAQ:SUPN) reported $0.69 earnings per share (EPS) to beat the analysts' consensus estimate of $0.44 by $0.25. Learn more on analysts' earnings estimate vs. SUPN's actual earnings. How can I listen to Supernus Pharmaceuticals's earnings conference call? The conference call for Supernus Pharmaceuticals's latest earnings report can be listened to online. Listen to Conference Call How can I read Supernus Pharmaceuticals's conference call transcript? The conference call transcript for Supernus Pharmaceuticals's latest earnings report can be read online. Read Transcript How can I view Supernus Pharmaceuticals's earnings report? Supernus Pharmaceuticals's earnings report can be found in their filing with the SEC. View SEC filing How much revenue does Supernus Pharmaceuticals generate each year? Supernus Pharmaceuticals (NASDAQ:SUPN) has a recorded annual revenue of $651.97 million. How much profit does Supernus Pharmaceuticals generate each year? Supernus Pharmaceuticals (NASDAQ:SUPN) has a recorded net income of $1.32 million. SUPN has generated $1.07 earnings per share over the last four quarters. What is Supernus Pharmaceuticals's price-to-earnings ratio? Supernus Pharmaceuticals (NASDAQ:SUPN) has a trailing price-to-earnings ratio of 33.11 and a forward price-to-earnings ratio of 14.95. What is Supernus Pharmaceuticals's EPS forecast for next year? Supernus Pharmaceuticals's earnings are expected to decrease from $2.37 per share to $1.40 per share in the next year, which is a -40.93% change. More Earnings Resources from MarketBeat Related Companies JAZZ Earnings Results CORT Earnings Results PRGO Earnings Results PCRX Earnings Results OMER Earnings Results NKTR Earnings Results ASMB Earnings Results CPIX Earnings Results LLY Earnings Results JNJ Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings This Indicator called BOTH NVDA rallies (Ad)Rarely would I label something as “the best” But in this rare instance, I believe this is THE BEST indicator for trading Nvida’s stock. Except, it’s not another tech stock like Nvidia. But rather a stock hiding in broad daylight… So, if you’d like to see what this stock is… Click this link here. This page (NASDAQ:SUPN) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Supernus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Supernus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
